CTI Website
  • Company
    • About Us
    • Leadership
    • Partnering
    • Contact
  • Medicines
    • VONJO® (pacritinib)
    • CTI Access
    • Medicine Support
    • Compliance & Transparency
  • Development
    • Development Overview
    • Myelofibrosis Program
    • Clinical Trials
    • Expanded Access
    • Publications & Posters
  • Careers
    • Our Culture
    • Job Openings
    • Diversity & Inclusion
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • Annual Report
      • Quarterly Reports
      • Stockholder Meeting
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Whistleblower Hotline
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • Contact IR
  • Contact
  • Patient Resources
  • Contact
  • Patient Resources
Select Page

Pacritinib

by [email protected] | Sep 28, 2021

Footer logo

Company

  • About Us
  • Leadership
  • Partnering
  • Contact

Medicines

  • VONJO® (pacritinib)
  • CTI Access
  • Medicine Support
  • Compliance & Transparency

Development

  • Development Overview
  • Myelofibrosis Program
  • Clinical Trials
  • Expanded Access
  • Publications & Posters

Careers

  • Our Culture
  • Job Openings
  • Diversity & Inclusion

Investors & Media

  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
  • Financial Information
  • Corporate Governance
  • Investor Resources
Footer logo
© 2022 CTI BIOPHARMA CORP. CTI and VONJO are trademarks of CTI BioPharma Corp.
  • Privacy Policy
  • Terms of Use

This site uses cookies to improve the browsing experience. Please visit our Privacy Policy page for more information.

Accept

Now approved in the U.S.

View Press Release
Continue to ctibiopharma.com